Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick Stiff, Simonetta Viviani, Veronika Bachanova, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham

Research output: Article

36 Citations (Scopus)

Fingerprint Dive into the research topics of 'Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds